CTI BioPharma Reports Second Quarter 2020 Financial Results
CTI BioPharma Corp. (Nasdaq: CTIC) reported its financial results for Q2 2020, revealing an operating loss of $10.0 million, slightly improved from $11.0 million in Q2 2019. For the six months ended June 30, 2020, the operating loss was $21.9 million, up from $21.5 million in 2019. The company faced no revenue during this period, contrasting with $0.4 million and $1.1 million in the same periods of 2019. A net loss of $14.0 million was recorded for Q2 2020, equal to $(0.19) per share. Cash reserves remain robust at $70.1 million, forecasted to sustain operations through Q4 2021.
- Cash and short-term investments totaled $70.1 million, providing financial stability.
- Operating loss for Q2 2020 improved slightly compared to Q2 2019.
- No revenue recognized for Q2 and six months ended June 30, 2020.
- Enrollment rate for the PACIFICA Phase 3 trial is lower than expected, leading to a six-month delay.
- Net loss for Q2 2020 increased compared to the same period in 2019.
SEATTLE, Aug. 6, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the second quarter and six months ended June 30, 2020.
"This past quarter we announced enrollment of the first patient in our PRE-VENT Phase 3 clinical trial of pacritinib in hospitalized patients with severe COVID-19, an important step for CTI as we work to provide a new therapeutic option for COVID-19 patients," said Adam R. Craig, M.D., Ph.D. "With regards to the PACIFICA Phase 3 trial, we continue to enroll patients but the enrollment rate is lower than planned due to the COVID-19 pandemic and we now anticipate at least a six-month delay in the trial. However, given our cash runway into Q4 2021, we remain confident in our ability to successfully execute on the development of pacritinib for the treatment of severely thrombocytopenic myelofibrosis patients."
Second Quarter Financial Results
Operating loss was
No revenues were recognized for the three and six months ended June 30, 2020, while revenues of
Net loss for the three months ended June 30, 2020 was
As of June 30, 2020, cash, cash equivalents and short-term investments totaled
About CTI BioPharma Corp.
We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.
Forward-Looking Statements
Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: our ability to conduct and complete clinical trials in our currently anticipated timeframes; our ability to successfully demonstrate the safety and efficacy of pacritinib; our expectations regarding the completion and outcome of our PACIFICA Phase 3 trial and our PRE-VENT Phase 3 trial; the risk that the FDA may determine that the benefit/risk profile of pacritinib at the dose selected for the PACIFICA Phase 3 trial does not support approval; the risk that the FDA may determine that the benefit/risk profile of pacritinib in the PRE-VENT Phase 3 trial does not support approval or requires additional clinical data for approval; the risk that pacritinib may fail in its development through our PACIFICA and PRE-VENT trial; our ability to submit an NDA for pacritinib in the timeline currently anticipated; our ability to receive regulatory approval for pacritinib pursuant to the accelerated approval pathway or at all; the risk that pacritinib may be delayed to a point where it is not commercially viable; the accuracy of our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations; risks and uncertainties related to the COVID-19 pandemic as it relates to our operations and ongoing clinical trials; and those risks more fully discussed in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2019 and subsequent quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions. All other trademarks belong to their respective owner.
CTI BioPharma Investor Contacts:
Maeve Conneighton/Maghan Meyers
+212-600-1902
cti@argotpartners.com
(tables follow)
CTI BioPharma Corp. Condensed Consolidated Statements of Operations (In thousands, except per share amounts) (unaudited)
| |||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
2020 | 2019 | 2020 | 2019 | ||||||||||||
License and contract revenues | $ | — | $ | 416 | $ | — | $ | 1,056 | |||||||
Operating costs and expenses: | |||||||||||||||
Research and development | 6,199 | 6,356 | 9,463 | 11,528 | |||||||||||
General and administrative | 3,797 | 5,053 | 8,264 | 10,259 | |||||||||||
Restructuring expenses | — | — | — | 794 | |||||||||||
Other operating expenses | — | — | 4,200 | — | |||||||||||
Total operating costs and expenses | 9,996 | 11,409 | 21,927 | 22,581 | |||||||||||
Loss from operations | (9,996) | (10,993) | (21,927) | (21,525) | |||||||||||
Non-operating income (expense): | |||||||||||||||
Interest income | 43 | 347 | 162 | 727 | |||||||||||
Interest expense | (137) | (269) | (304) | (563) | |||||||||||
Amortization of debt discount and issuance costs | (130) | (130) | (260) | (260) | |||||||||||
Foreign exchange (loss) gain | (6) | 69 | (83) | (169) | |||||||||||
Loss on dissolution of majority-owned subsidiary | (3,774) | — | (3,774) | — | |||||||||||
Total non-operating (expense) income, net | (4,004) | 17 | (4,259) | (265) | |||||||||||
Net loss before noncontrolling interest | (14,000) | (10,976) | (26,186) | (21,790) | |||||||||||
Noncontrolling interest | — | 5 | — | 5 | |||||||||||
Net loss | $ | (14,000) | $ | (10,971) | $ | (26,186) | $ | (21,785) | |||||||
Basic and diluted net loss per common share | $ | (0.19) | $ | (0.19) | $ | (0.38) | $ | (0.38) | |||||||
Shares used in calculation of basic and diluted net loss per common share: | 73,685 | 57,973 | 68,073 | 57,973 | |||||||||||
Balance Sheet Data (unaudited): | (amounts in thousands) | |||||||
June 30, | December 31, | |||||||
2020 | 2019 | |||||||
Cash and cash equivalents | $ | 70,110 | $ | 31,144 | ||||
Short-term investments | — | 2,522 | ||||||
Working capital | 57,782 | 17,092 | ||||||
Total assets | 76,412 | 46,280 | ||||||
Current portion of long-term debt | 4,812 | 4,812 | ||||||
Long-term debt, less current portion | 2,049 | 4,455 | ||||||
Total stockholders' equity | 56,863 | 17,930 | ||||||
View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-reports-second-quarter-2020-financial-results-301107949.html
SOURCE CTI BioPharma Corp.
